NCT00142168 - CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

May 31, 2006

Study Completion Date

April 30, 2008

Conditions

Waldenstrom's Macroglobulinemia

Interventions

DRUG

CC-5103 (lenalidomide)

Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)

DRUG

Rituximab

Begins on week 2 of treatment and is given intravenously once a week for 4 weeks

Trial Locations (2)

Dana-Farber Cancer Institute, Boston

Beth Israel Deaconess Medical Center, Boston